The Role of Dopaminergic Systems in the Regulation of Sleep and Wakefulness in Neurodegenerative Diseases

The Role of Dopaminergic Receptors in Sleep-Wake Regulation

Dopamine acts on its receptors, five types, namely D1, D2, D3, D4, and D5, all of which are involved in the regulation of sleep and wakefulness. The D1 and D2 receptors are mainly involved in the regulation of arousal and maintaining wakefulness. Data also suggest that stimulating D1-like receptors increases wakefulness and blocks sleep attacks in animal models, while D2-like receptors play an important role in regulation of sleep attacks and cataplexy, particularly in narcolepsy.

In neurodegenerative diseases, the localization of these dopamine receptors may result in sleep-wake cycle disturbances. For example, in Parkinson’s disease, dopaminergic agents that act on D2 receptors can help control motor dysfunction but can also cause iatragenically shift the sleep/wake cycle. It is seen that an identical neurotransmitter can have opposite effects, and this duality is also seen in the use of dopamine for sleep regulation in Parkinson’s disease. The problem of managing both motor as well as nonmotor symptoms of neurodegenerative diseases is a challenging and difficult one.

Narcolepsy and Dopaminergic Dysfunction

Narcolepsy is another sleep disorder associated with DA dysregulation of CNS activity. Unlike Parkinson’s disease, in which dopaminergic neurons are lost, narcolepsy involves the loss of hypocretin (orexin) neurons in the hypothalamus. Hypocretin is a neuropeptide that is essential in the regulation of wakefulness; its deficiency results in excessive daytime sleepiness and cataplexy.

In addition to hypocretin deficiency, nopol of the dopaminergic system is also key in regulating sleep attacks and cataplexy that characterize narcolepsy. It has been established that drugs acting on dopamine receptors can help to regulate these symptoms, and in particular D2-like antagonists helping to lessen cataplexy in animal models of the disease.

For the treatment of the excessive daytime sleepiness seen in narcolepsy, dopamine agonists, for example, the amphetamine class of drugs, are usually administered because they help to increase dopamine in the brain. These medications act through the dopaminergic system to increase wakefulness, and their administration should be done cautiously because they may cause sleep disruptions.

REM Sleep Behavior Disorder and Dopaminergic Pathways

RBD is considered the early manifestation of neurodegenerative disorders for which Parkinson’s disease and dementia with Lewy bodies are typical. In RBD, patients have movements during REM sleep because they lose normal muscle atonia that is necessary to prevent acting out dream images.

Although the precise cause of RBD is unknown, the pathophysiology is related to dopaminergic system disorder, notably in the brainstem component of REM sleep regulation circuits. Dopaminergic degeneration of these areas results in disinhibition of motor paths during REM sleep and the ability of the patients to physically execute dream narratives. RBD is a sleep disorder characterized by awakenings that disrupt the normal architecture of sleep, but it is equally significant as a marker of early synucleinopathies in that most RBD patients with primary symptoms will go on to develop Parkinson’s disease or other related neurodegenerative conditions.

Dopaminergic Therapies for Sleep Disorders in Neurodegenerative Diseases

Since dopamine plays a pivotal role in the regulation of REM sleep and wakefulness, it is not surprising that many therapies for sleep disorders in neurodegenerative diseases are directed at the dopaminergic system. Pramipexole, ropinirole, and other dopamine agonists are the drugs of choice for treating restless legs syndrome, which is reported in more than 60% of patients with Parkinson’s disease. These drugs assist in lessening motor activity during sleep, hence increasing sleep quality.

However, when it comes to applying dopaminergic therapies to sleep disorders, there are certain problems that might arise. Dopamine agonists can help with symptoms of PD, but at the same time they cause other symptoms, including insomnia and daytime somnolenPD. Additionally, a side effect that can be caused by long-term use of these medications includes dopamine dysregulation syndrome, in which the patients develop addictive behaviors resulting from elevated dopamine levels.

However, for treating REM sleep behavior disorder in Parkinson’s disease, dopamine agonists are not the sole treatments available; melatonin and clonazepam are also effective. These treatments get to correct abnormal sleep patterns by minimizing REM sleep while at the same time not compromising alertness during the day.

The Future of Sleep and Dopaminergic Research

The role of dopamine on sleep control and neurodegenerative illnesses is still under investigation. Despite a comprehensive characterization of multiple dopaminergic neuronal circuits involved in the control of sleep and wakefulness, difficulties in understanding the precise ways by which dopamine regulation of these processes occurs in conditions such as Parkinson’s disease, narcolepsy, or RBD remain, which is very essential for the enhancement of therapies. Subsequent studies may aim at finding other dopaminergic receptors that can increase sleep in addition to reducing the progression of motor and cognitive flavors.

In addition, continued innovation in neuroimaging techniques and biomarkers to better understand the development of sleep disturbances in NDs should occur. These tools will enable clinicians to make necessary adjustments in treatment strategy based on the effect of dopaminergic therapies on sleep and help patients to take needed dopaminergic medications without adverse consequences.

Conclusion

The dopaminergic system is critical to the sleep/wake cycle both at the system and molecular level, especially in neurodegenerative diseases. A disruption of dopamine signaling leads to disturbances in sleep and wake regulation and accounts for many sleep disorders such as insomnia, excessive daytime sleepiness, REM sleep behavior disorder, and cataplexy. Understanding how dopamine modulates these processes is crucial for designing a therapy targeting both motor and nonmotor manifestations of other neurodegenerative diseases such as Parkinsonism or narcolepsy. As the story of dopaminergic pathways unfolds and more is understood about the underlying pathophysiology, there might well be new treatment approaches that will see people with PD sleeping better and feeling better generally.

References

1. Burgess, C.R., Tse, G., Gillis, L. and Peever, J.H., 2010. Dopaminergic regulation of sleep and cataplexy in a murine model of narcolepsy. Sleep, 33(10), pp.1295-1304.
2. Chaudhuri, K.R., Martinez‐Martin, P., Schapira, A.H., Stocchi, F., Sethi, K., Odin, P., Brown, R.G., Koller, W., Barone, P., MacPhee, G. and Kelly, L., 2006. International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Movement disorders: official journal of the Movement Disorder Society, 21(7), pp.916-923.
3. Postuma, R.B., Gagnon, J.F. and Montplaisir, J.Y., 2013. REM sleep behavior disorder and prodromal neurodegeneration–where are we headed?. Tremor and Other Hyperkinetic Movements, 3.
4. Fairfoul, G., McGuire, L.I., Pal, S., Ironside, J.W., Neumann, J., Christie, S., Joachim, C., Esiri, M., Evetts, S.G., Rolinski, M. and Baig, F., 2016. Alpha‐synuclein RT‐Qu IC in the CSF of patients with alpha‐synucleinopathies. Annals of clinical and translational neurology, 3(10), pp.812-818.
5. Iranzo, A., Fernández-Arcos, A., Tolosa, E., Serradell, M., Molinuevo, J.L., Valldeoriola, F., Gelpi, E., Vilaseca, I., Sánchez-Valle, R., Lladó, A. and Gaig, C., 2014. Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. PloS one, 9(2), p.e89741.
6. Osler, M. and Jørgensen, M.B., 2020. Associations of benzodiazepines, Z-drugs, and other anxiolytics with subsequent dementia in patients with affective disorders: a nationwide cohort and nested case-control study. American Journal of Psychiatry, 177(6), pp.497-505.
7. Höglinger, G.U., Respondek, G., Stamelou, M., Kurz, C., Josephs, K.A., Lang, A.E., Mollenhauer, B., Müller, U., Nilsson, C., Whitwell, J.L. and Arzberger, T., 2017. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Movement disorders, 32(6), pp.853-864.